Cancer
Merck_MK-2870-010
Breast Cancer
An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer
Contact Research Team:
[email protected]
Site principal investigator:
Timothy Pluard, MD
Learn more about this study:
NCT06312176